ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.34 ▼ -11.70 (-4.25%)HPE: $70.10 ▼ -3.36 (-4.57%)AMD: $590.61 ▼ -17.49 (-2.88%)DELL: $574.44 ▼ -11.62 (-1.98%)PANW: $399.92 ▼ -18.86 (-4.50%)MRNA: $214.33 ▼ -10.67 (-4.74%)AAPL: $339.63 ▲ 2.99 (0.89%)AMZN: $259.90 ▼ -2.53 (-0.96%)MSFT: $540.03 ▲ 4.96 (0.93%)NVDA: $226.58 ▼ -2.70 (-1.18%)CIEN: $403.01 ▼ -46.76 (-10.40%)DDOG: $288.28 ▼ -4.98 (-1.70%)SNPS: $503.23 ▼ -6.77 (-1.33%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

Tectonic Therapeutic, Inc.

TECX - NASDAQ

Identifiants & Marche

Ticker TECX
ISIN US8789721086
CIK 0001681087
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.